doi:10.3969/j.issn.1004-583X.2023.05.017

Abstract

CLC Number:

R735.7

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.05.017

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I5/473

References 40

[1]	Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. Anunusual tumor with distinctive clinical and pathological features[J]. Am J Med, 1965, 38: 241-256. doi: 10.1016/0002-9343(65)90178-6 URL
[2]	Lang H, Kaiser GM, Zöpf T, et al. Zentrale gallengangskarzinome[Surgical therapy of hilar cholangiocarcinoma][J]. Chirurg, 2006, 77(4): 325-334. pmid: 16568258
[3]	Iwasaki A, Kubota K, Kurita Y, et al. The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2020, 27(10): 700-711. doi: 10.1002/jhbp.v27.10 URL
[4]	Marsh Rde W, Alonzo M, Bajaj S, et al. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: Multidisciplinary management[J]. J Surg Oncol, 2012, 106(3): 339-345. doi: 10.1002/jso.23027 pmid: 22488601
[5]	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. doi: 10.1056/NEJMoa0908721 URL
[6]	Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: A multicentre randomised phase II study-The UK ABC-01 Study[J]. Br J Cancer, 2009, 101(4): 621-627. doi: 10.1038/sj.bjc.6605211
[7]	Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study[J]. J Clin Oncol, 2019, 37(8): 658-667. doi: 10.1200/JCO.18.00050 pmid: 30707660
[8]	Kobayashi S, Eguchi H, Kanai M, et al. Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study)[J]. J Clin Oncol, 2019, 37(15_suppl): 4093. doi: 10.1200/JCO.2019.37.15_suppl.4093 URL
[9]	董家刚, 庞显伦. 改良胆管内灌注化疗在晚期肝门胆管癌中的应用研究[J]. 航空航天医学杂志, 2018, 29(3): 257-259.
[10]	严庆, 冯铭彬, 朱太峰, 等. 术后辅助化疗对肝门部胆管癌切除术后患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2021, 10(5): 459-463.
[11]	尹大龙, 刘连新. 新辅助治疗在局部晚期肝门部胆管癌术前降期治疗中的应用价值[J]. 中华消化外科杂志, 2020, 19(12):1253-1256.
[12]	Soumarová R, Gürlich R, Hajer J, et al. The current role of radiotherapy and systemic therapy in the multidisciplinary treatment of cholangiocarcinoma[J]. Cas Lek Cesk, 2019, 158(2): 78-82. pmid: 31109168
[13]	周传国, 张勇, 黄强, 等. 125I粒子条联合胆道金属支架植入术治疗恶性肝门区胆管梗阻[J]. 中国介入影像与治疗学, 2018, 15(12): 717-721.
[14]	符誉, 翁杰, 韩霖, 等. 经皮胆道支架置入联合125I粒子腔内照射治疗肝门部胆管癌的疗效观察[J]. 广西医科大学学报, 2018, 35(11): 1503-1507.
[15]	Lei QY, Jiao DC, Han XW. Novel brachytherapy drainage tube loaded with double ¹²⁵I strands for hilar cholangiocarcinoma: A case report[J]. World J Clin Cases, 2020, 8(19): 4603-4608. doi: 10.12998/wjcc.v8.i19.4603 URL
[16]	李刚, 王全义, 苏金旺, 等. 新型125I双链胆道引流管治疗胆管癌合并黄疸的近期疗效(附9例报告)[J]. 中华介入放射学电子杂志, 2021, 9(4): 403-406.
[17]	闫炫炫, 李多富, 李汛. 光动力疗法在不可切除肝门部胆管癌中的应用[J]. 中国普外基础与临床杂志, 2018, 25(4): 488-492.
[18]	Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma[J]. Cancer Treat Res Commun, 2021, 27: 100337.
[19]	Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7(11): 1669-1677. doi: 10.1001/jamaoncol.2021.3836 pmid: 34554208
[20]	Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 803-815. doi: 10.1016/S2468-1253(21)00196-5 URL
[21]	Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: Implications for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2016, 23(8): 2610-2617. doi: 10.1245/s10434-016-5101-y pmid: 27012989
[22]	Kang J, Jeong JH, Hwang HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer: Tumor proportion score as a potential biomarker for response[J]. Cancer Res Treat, 2020, 52(2): 594-603. doi: 10.4143/crt.2019.493 pmid: 32019287
[23]	Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: A non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(8): 611-621. doi: 10.1016/S2468-1253(19)30086-X URL
[24]	Zhang Q, Liu X, Wei S, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: A single-arm, open-label, phase II study[J]. Front Oncol, 2021, 11: 751391.
[25]	Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study[J]. Lancet Gastroenterol Hepatol, 2022, 7(6): 522-532. doi: 10.1016/S2468-1253(22)00043-7 URL
[26]	Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2023.
[27]	Agostinis P, Buytaert E, Breyssens H, et al. Regulatory pathways in photodynamic therapy induced apoptosis[J]. Photochem Photobiol Sci, 2004, 3(8): 721-729. doi: 10.1039/b315237e URL
[28]	Casas A, Di Venosa G, Hasan T, et al. Mechanisms of resistance to photodynamic therapy[J]. Curr Med Chem, 2011, 18(16): 2486-2515. doi: 10.2174/092986711795843272 pmid: 21568910
[29]	陈士明, 娄玥, 方煊, 等. 光动力疗法联合支架引流与单独支架引流治疗不可切除胆管癌疗效的Meta分析[J]. 中华肝胆外科杂志, 2018, 24(9): 616-621.
[30]	Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: Palliative photodynamic therapy plus stenting is comparable to r1/r2 resection[J]. Ann Surg, 2006, 244(2): 230-239. doi: 10.1097/01.sla.0000217639.10331.47 pmid: 16858185
[31]	Chen P, Yang T, Shi P, et al. Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: A meta-analysis[J]. Photodiagnosis Photodyn Ther, 2022, 37: 102712.
[32]	Buerlein RCD, Wang AY. Endoscopic retrograde cholangiopancreatography-guided ablation for cholangiocarcinoma[J]. Gastrointest Endosc Clin N Am, 2019, 29(2): 351-367. doi: S1052-5157(18)30838-9 pmid: 30846158
[33]	Takenaka M, Lee TH. Role of radiofrequency ablation in advanced malignant hilar biliary obstruction[J]. Clin Endosc, 2023, 56(2): 155-163. doi: 10.5946/ce.2022.218 URL
[34]	Cho JH, Lee KH, Kim JM, et al. Safety and effectiveness of endobiliary radiofrequency ablation according to the different power and target temperature in a swine model[J]. J Gastroenterol Hepatol, 2017, 32(2): 521-526. doi: 10.1111/jgh.2017.32.issue-2 URL
[35]	Smith I, Kahaleh M. Biliary tumor ablation with photodynamic therapy and radiofrequency ablation[J]. Gastrointest Endosc Clin N Am, 2015, 25(4): 793-804. doi: 10.1016/j.giec.2015.06.013 pmid: 26431605
[36]	Wang J, Zhao L, Zhou C, et al. Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for nonresectable malignant biliary obstruction improves stent patency but not survival[J]. Medicine (Baltimore), 2016, 95(15): e3329. doi: 10.1097/MD.0000000000003329 URL
[37]	Vogel JA, van Veldhuisen E, Agnass P, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: A systematic review of experimental studies[J]. PLoS One, 2016, 11(11): e0166987.
[38]	郭凯, 李晓勇, 周百中, 等. 纳米刀消融治疗不可切除肝门部胆管癌的临床价值[J]. 中国普通外科杂志, 2020, 29(1): 78-84.
[39]	陈艳军, 程冰冰, 郜宇, 等. 纳米刀消融联合胆道支架治疗不可切除肝门部胆管癌探讨[J]. 实用医学杂志, 2019, 35(19): 3115-3118.
[40]	Hsiao CY, Yang PC, Li X, et al. Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma[J]. Sci Rep, 2020, 10(1): 10883. doi: 10.1038/s41598-020-67772-2

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Ya, Du Taoming, Qiu Shixiang, Chen Chao, Zhong Liming. Study on brain functional connectivity in patients with liver cancer with depression [J]. Clinical Focus, 2023, 38(6): 532-536.
[2]	Li Ya, Qiu Shixiang, Chen Chao, Zhong Liming. Depression-related factors and corresponding correlations with quality of life in patients with hepatocellular carcinoma [J]. Clinical Focus, 2022, 37(6): 539-543.
[3]	Guo Xiaojun, Kong Yanliang, Liu Tao, Cheng Zhengxiang, Zhang Rui, Fan Lei. CT-guided percutaneous radiofrequency ablation for hepatic carcinoma [J]. Clinical Focus, 2021, 36(9): 807-810.
[4]	Xie Zhihai, Zhou Zhicong, Gui Yuan, Sun Jingfeng. Differential expression of IGF1R antisense noncoding RNA in hepatocellular carcinoma [J]. Clinical Focus, 2021, 36(7): 620-622.
[5]	Liu Huimin,Liu Ping. Study on using ROC curve evaluation of α-L-fucosidase, 5'-nucleo tidase and alpha fetoprotein diagnostic and predictive value in hepatocellular carcinoma [J]. Clinical Focus, 2016, 31(4): 414-417.
[6]	Gu Tao;Liu Lijie;Meng Wei;Hua Haixia;Zhang Yunjie;Zhang Qiuli. Level and significance of circulating histones in patients with hepatocellular carcinoma treated by radiofrequency ablation [J]. Clinical Focus, 2015, 30(12): 1386-1389.
[7]	Zhang Zhiyong;Zhang Qian. Change and clinical significance of serum microRNA-106b expression in hepatocarcinoma patients after transcatheter hepatic arterial chemoembolization [J]. Clinical Focus, 2015, 30(12): 1390-1.39214e+007.
[8]	Zheng Jianxiao;Wu Jinming. Effect of Fuzhengbuxu decotion on T cell subsets and angiogenesis related factors of patients with primary hepatic carcinoma [J]. Clinical Focus, 2015, 30(9): 1036-1038.
[9]	YANG Shou-ping;LI Hai-ying;ZHANG Li. Diagnostic value of combined detection of soluble human leukocyte antigen-G, alpha fetoprotein and alpha fetoprotein-L3 in primary hepatocellular carcinoma [J]. Clinical Focus, 2014, 29(8): 888-890891.
[10]	. [J]. Clinical Focus, 2014, 29(6): 691-691.
[11]	YUAN Su-yun;LAN Tao;ZHOU Guo-qing;WANG Gui-hua;LI Zhi-juan. Effects of ubenimex capsules on serum levels of vascular endothelial growth factors in primary liver carcinoma [J]. CLINICAL FOCUS, 2014, 29(3): 318-320.
[12]	LI Li;LIU Li-feng;WU Yan-ning;LI Qing;CHEN De-xi. Mutation research of c-myc gene in hepatocellular carcinoma [J]. CLINICAL FOCUS, 2013, 28(9): 976-978.
[13]	. [J]. Clinical Focus, 2013, 28(4): 431-432.
[14]	LAN Tao;YUAN Jian-lei;WANG Zhao. Expression and significance of Bcl-2, vascular endothelial growth factor in liver cancer [J]. Clinical Focus, 2013, 28(2): 130-0.
[15]	. [J]. Clinical Focus, 2012, 27(19): 1718-1721.